Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Hochschild said it remains on track to meet its overall attributable production target of 291,000 to 319,000 gold-equivalent ounces. It is also expected to meet its all-in sustaining cost target of $1 ...

The U.K. international financial services business said Wednesday that group net receivables rose 14% to 1.01 billion pounds ($1.35 billion). It expects growth to continue to accelerate through the ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

As the brewer’s new chief executive settles into the job, TD Cowen analysts believe the company needs to do more than simply get leaner.

TeamViewer reported lower net income under IFRS for the third quarter and lowered its full-year earnings outlook.

Halfords Group posted an increase in sales for its first half and said its balance sheet was also fortified by strong cash generation. The motoring-and-cycling products retailer said Wednesday that ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Cosmo Energy Holdings Co. intends to delay its plan of more than quadrupling the scale of its offshore wind power generation by 2030, its group CEO told The Yomiuri Shimbun.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Innovent Biologics is teaming up with Japan's Takeda Pharmaceutical to work on cancer therapies, a deal that could net the Chinese drugmaker up to US$11.4 billion.